Larry Zeitlin
Principal investigator.
Biotech
Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2014First federal award
$9.8MFederal grants as PI14 awards
0Patents grantedNone matched
0PapersOpenAlex
Federal awards and patents by year
AwardsPatents
14 awards · $9.8M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Jun 9, 2025 | NIH | SBIR Phase II A Novel Cost-Effective Multispecific Therapeutic for Dengue | $295K | MAPP BIOPHARMACEUTICAL, INC. |
| Jun 15, 2022 | NIH | SBIR Phase II Development of highly potent human monoclonal for RSV immuno-prophylaxis | $948K | MAPP BIOPHARMACEUTICAL, INC. |
| Jul 8, 2021 | NIH | SBIR Phase II Development of highly potent human monoclonal for RSV immuno-prophylaxis | $801K | MAPP BIOPHARMACEUTICAL, INC. |
| Jul 28, 2020 | DoD | STTR Phase II Marburg Virus Prophylactic Medical Countermeasure | $999K | MAPP BIOPHARMACEUTICAL, INC. with Mapp Biopharmaceutical |
| Jul 2, 2020 | NIH | SBIR Phase II Development of highly potent human monoclonal for RSV immuno-prophylaxis | $2.7M | MAPP BIOPHARMACEUTICAL, INC. |
| Dec 28, 2018 | NIH | SBIR Phase I Development of highly potent human monoclonals for RSV immunoprophylaxis | $300K | MAPP BIOPHARMACEUTICAL, INC. |
| Sep 27, 2018 | DoD | STTR Phase I Marburg Virus Prophylactic Medical Countermeasure | $150K | MAPP BIOPHARMACEUTICAL, INC. with University of Texas Medical Branch |
| Jun 29, 2018 | NIH | SBIR Phase II Post-exposure immunotherapy for ricin exposure | $298K | MAPP BIOPHARMACEUTICAL, INC. |
| Jan 15, 2018 | NIH | SBIR Phase I Development of highly potent human monoclonals for RSV immunoprophylaxis | $600K | MAPP BIOPHARMACEUTICAL, INC. |
| Aug 1, 2016 | NIH | SBIR Phase I Rapid Response Agents Against Filovirus Outbreaks Using Vectored Immunoprophylaxis | $240K | MAPP BIOPHARMACEUTICAL, INC. |
| Jun 13, 2016 | NIH | SBIR Phase II An Immunoprotectant for Marburg Virus | $1000K | MAPP BIOPHARMACEUTICAL, INC. |
| Jun 24, 2015 | NIH | SBIR Phase II An Immunoprotectant for Marburg Virus | $1000K | MAPP BIOPHARMACEUTICAL, INC. |
| Jun 18, 2015 | NIH | SBIR Phase I A human monoclonal for RSV prophylaxis | $300K | MAPP BIOPHARMACEUTICAL, INC. |
| Dec 11, 2014 | DoD | SBIR Phase I Ricin Toxin Protective Monoclonal Antibodies with Improved Serum Half-Life | $150K | MAPP BIOPHARMACEUTICAL, INC. |
Peer ranks
Federal funding#63
Awards as PI#57
Patents#273
Companies
- MAPP BIOPHARMACEUTICAL, INC.Linked by awards · Biotech
Research institutions
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.